

# Ulrich Strych

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2134051/publications.pdf>

Version: 2024-02-01

85  
papers

3,914  
citations

156536

32  
h-index

162838

57  
g-index

100  
all docs

100  
docs citations

100  
times ranked

6750  
citing authors

#	ARTICLE	IF	CITATIONS
1	Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. <i>Protein Expression and Purification</i> , 2022, 190, 106003.	0.6	21
2	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
3	Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. <i>Frontiers in Immunology</i> , 2022, 13, 800295.	2.2	4
4	Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e356-e365.	4.7	41
5	Vaxi-DL: A web-based deep learning server to identify potential vaccine candidates. <i>Computers in Biology and Medicine</i> , 2022, 145, 105401.	3.9	7
6	Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. <i>Vaccine</i> , 2022, 40, 3655-3663.	1.7	21
7	CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme <i>Borreliae</i> Clearance. <i>Infection and Immunity</i> , 2022, 90, .	1.0	3
8	Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. <i>Expert Review of Vaccines</i> , 2022, 21, 1405-1417.	2.0	1
9	A scalable and reproducible manufacturing process for <i>Phlebotomus papatasi</i> salivary protein PpSP15, a vaccine candidate for leishmaniasis. <i>Protein Expression and Purification</i> , 2021, 177, 105750.	0.6	4
10	Correlates and disparities of intention to vaccinate against COVID-19. <i>Social Science and Medicine</i> , 2021, 272, 113638.	1.8	334
11	Recombinant protein vaccines, a proven approach against coronavirus pandemics. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 71-82.	6.6	157
12	SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2356-2366.	1.4	64
13	The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. <i>American Journal of Preventive Medicine</i> , 2021, 60, 605-613.	1.6	28
14	Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. <i>Journal of Infectious Diseases</i> , 2021, 224, 938-948.	1.9	32
15	Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 4153-4165.	1.7	37
16	Facing the challenges of multidrug-resistant <i>Acinetobacter baumannii</i> : progress and prospects in the vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3784-3794.	1.4	21
17	Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129893.	1.1	49
18	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	5.6	53

#	ARTICLE	IF	CITATIONS
19	Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. <i>Scientific Reports</i> , 2021, 11, 17626.	1.6	42
20	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2021, , eabj5305.	5.8	4
21	The complete genome sequence of the nitrile biocatalyst <i>Rhodococcus rhodochrous</i> ATCC BAA-870. <i>BMC Genomics</i> , 2020, 21, 3.	1.2	7
22	Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. <i>Vaccine</i> , 2020, 38, 7533-7541.	1.7	84
23	Coronavirus vaccine-associated lung immunopathology-what is the significance?. <i>Microbes and Infection</i> , 2020, 22, 403-404.	1.0	15
24	Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. <i>American Journal of Preventive Medicine</i> , 2020, 59, 493-503.	1.6	259
25	COVID-19 vaccines: neutralizing antibodies and the alum advantage. <i>Nature Reviews Immunology</i> , 2020, 20, 399-400.	10.6	74
26	The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. <i>Vaccine</i> , 2020, 38, 3261-3270.	1.7	7
27	Process Characterization and Biophysical Analysis for a Yeast-Expressed <i>Phlebotomus papatasi</i> Salivary Protein (PpSP15) as a <i>Leishmania</i> Vaccine Candidate. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1673-1680.	1.6	8
28	The SARS-CoV-2 Vaccine Pipeline: an Overview. <i>Current Tropical Medicine Reports</i> , 2020, 7, 61-64.	1.6	403
29	Protective immunity elicited by the nematode-conserved As37 recombinant protein against <i>Ascaris suum</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008057.	1.3	25
30	Neglected Parasitic Infections and the Syndemic Anemia Vaccines for Africa. , 2019, , 75-85.		2
31	Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens. <i>Vaccines</i> , 2019, 7, 131.	2.1	29
32	A method to probe protein structure from UV absorbance spectra. <i>Analytical Biochemistry</i> , 2019, 587, 113450.	1.1	37
33	Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. <i>Vaccine</i> , 2019, 37, 3704-3714.	1.7	12
34	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. <i>Vaccine</i> , 2018, 36, 1853-1862.	1.7	62
35	Characterization and Stability of <i>Trypanosoma cruzi</i> Tc24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1468-1473.	1.6	23
36	Covalent vaccination with <i>Trypanosoma cruzi</i> Tc24 induces catalytic antibody production. <i>Parasite Immunology</i> , 2018, 40, e12585.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 1961-1970.	1.6	95
38	A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. <i>Vaccine</i> , 2017, 35, 1410-1416.	1.7	1
39	Mutations to Cysteine Residues in the <i>Trypanosoma cruzi</i> B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. <i>Journal of Parasitology</i> , 2017, 103, 579-583.	0.3	3
40	Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 621-633.	1.4	39
41	Yeast-expressed recombinant As16 protects mice against <i>Ascaris suum</i> infection through induction of a Th2-skewed immune response. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005769.	1.3	30
42	The hookworm <i>Ancylostoma ceylanicum</i> intestinal transcriptome provides a platform for selecting drug and vaccine candidates. <i>Parasites and Vectors</i> , 2016, 9, 518.	1.0	19
43	Flotation Immunoassay: Masking the Signal from Free Reporters in Sandwich Immunoassays. <i>Scientific Reports</i> , 2016, 6, 24297.	1.6	11
44	Advancing a vaccine to prevent hookworm disease and anemia. <i>Vaccine</i> , 2016, 34, 3001-3005.	1.7	36
45	Advancing a vaccine to prevent human schistosomiasis. <i>Vaccine</i> , 2016, 34, 2988-2991.	1.7	90
46	Human anthelmintic vaccines: Rationale and challenges. <i>Vaccine</i> , 2016, 34, 3549-3555.	1.7	49
47	Status of vaccine research and development of vaccines for Chagas disease. <i>Vaccine</i> , 2016, 34, 2996-3000.	1.7	56
48	Vaccine Development Against Middle East Respiratory Syndrome. <i>Current Tropical Medicine Reports</i> , 2016, 3, 80-86.	1.6	2
49	Status of vaccine research and development of vaccines for leishmaniasis. <i>Vaccine</i> , 2016, 34, 2992-2995.	1.7	176
50	Expression and purification of an engineered, yeast-expressed <i>Leishmania donovani</i> nucleoside hydrolase with immunogenic properties. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-14.	1.4	12
51	New Vaccines for the World's Poorest People. <i>Annual Review of Medicine</i> , 2016, 67, 405-417.	5.0	52
52	Detection of Viruses By Counting Single Fluorescent Genetically Biotinylated Reporter Immunophage Using a Lateral Flow Assay. <i>ACS Applied Materials &amp; Interfaces</i> , 2015, 7, 2891-2898.	4.0	21
53	Label-free monitoring of individual DNA hybridization using SERS. <i>Proceedings of SPIE</i> , 2015, , .	0.8	0
54	Neglected Tropical Diseases among the Association of Southeast Asian Nations (ASEAN): Overview and Update. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003575.	1.3	97

#	ARTICLE	IF	CITATIONS
55	Enzymatic Synthesis of Magnetic Nanoparticles. <i>International Journal of Molecular Sciences</i> , 2015, 16, 7535-7550.	1.8	9
56	Aptamer-Phage Reporters for Ultrasensitive Lateral Flow Assays. <i>Analytical Chemistry</i> , 2015, 87, 11660-11665.	3.2	35
57	Sensitive Detection of Norovirus Using Phage Nanoparticle Reporters in Lateral-Flow Assay. <i>PLoS ONE</i> , 2015, 10, e0126571.	1.1	37
58	Label-free, in situ SERS monitoring of individual DNA hybridization in microfluidics. <i>Nanoscale</i> , 2014, 6, 8521-8526.	2.8	85
59	Investigation of the Essentiality of Glutamate Racemase in <i>Mycobacterium smegmatis</i> . <i>Journal of Bacteriology</i> , 2014, 196, 4239-4244.	1.0	15
60	Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation. <i>Biotechnology Letters</i> , 2014, 36, 1863-1868.	1.1	10
61	Purification and Characterization of Proteins. , 2014, , 731-742.		1
62	Functionalized viral nanoparticles as ultrasensitive reporters in lateral-flow assays. <i>Analyst, The</i> , 2013, 138, 5584.	1.7	29
63	Biophysical characterization of VEGFâ€™aHt DNA aptamer interactions. <i>International Journal of Biological Macromolecules</i> , 2013, 57, 69-75.	3.6	12
64	Detection and Typing of Viruses Using Broadly Sensitive Cocktail-PCR and Mass Spectrometric Cataloging. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 402-407.	1.2	4
65	A peroxidase-active aptazyme as an isothermally amplifiable label in an aptazyme-linked oligonucleotide assay for low-picomolar IgE detection. <i>Analyst, The</i> , 2012, 137, 5710.	1.7	9
66	Rare target enrichment for ultrasensitive PCR detection using cotâ€™rehybridization and duplex-specific nuclease. <i>Analytical Biochemistry</i> , 2012, 421, 81-85.	1.1	7
67	Recovery of Small DNA Fragments from Serum Using Compaction Precipitation. <i>PLoS ONE</i> , 2012, 7, e51863.	1.1	4
68	New Classes of Alanine Racemase Inhibitors Identified by High-Throughput Screening Show Antimicrobial Activity against <i>Mycobacterium tuberculosis</i> . <i>PLoS ONE</i> , 2011, 6, e20374.	1.1	38
69	The crystal structure of alanine racemase from <i>Streptococcus pneumoniae</i> , a target for structure-based drug design. <i>BMC Microbiology</i> , 2011, 11, 116.	1.3	30
70	DNAzyme-mediated recovery of small recombinant RNAs from a 5S rRNA-derived chimera expressed in <i>Escherichia coli</i> . <i>BMC Biotechnology</i> , 2010, 10, 85.	1.7	27
71	Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green. <i>Journal of Molecular Recognition</i> , 2009, 22, 154-161.	1.1	40
72	Biochemical and structural characterization of alanine racemase from <i>Bacillus anthracis</i> (Ames). <i>BMC Structural Biology</i> , 2009, 9, 53.	2.3	32

#	ARTICLE	IF	CITATIONS
73	The Alanine Racemase of <i>Mycobacterium smegmatis</i> Is Essential for Growth in the Absence of $\alpha$ -Alanine. <i>Journal of Bacteriology</i> , 2007, 189, 8381-8386.	1.0	50
74	Purification and preliminary crystallization of alanine racemase from <i>Streptococcus pneumoniae</i> . <i>BMC Microbiology</i> , 2007, 7, 40.	1.3	21
75	The 1.9 Å... Crystal Structure of Alanine Racemase from <i>Mycobacterium tuberculosis</i> Contains a Conserved Entryway into the Active Site. <i>Biochemistry</i> , 2005, 44, 1471-1481.	1.2	86
76	Crystal Structure at 1.45 Å... Resolution of Alanine Racemase from a Pathogenic Bacterium, <i>Pseudomonas aeruginosa</i> , Contains Both Internal and External Aldimine Forms. <i>Biochemistry</i> , 2003, 42, 14752-14761.	1.2	44
77	N(2)-Substituted D,L-Cycloserine Derivatives: Synthesis and Evaluation as Alanine Racemase Inhibitors. <i>Journal of Antibiotics</i> , 2003, 56, 160-168.	1.0	24
78	Mutant Analysis Shows that Alanine Racemases from <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> Are Dimeric. <i>Journal of Bacteriology</i> , 2002, 184, 4321-4325.	1.0	42
79	Characterization of the alanine racemases from two <i>Mycobacteria</i> . <i>FEMS Microbiology Letters</i> , 2001, 196, 93-98.	0.7	88
80	Characterization of the Alanine Racemases from <i>Pseudomonas aeruginosa</i> PAO1. <i>Current Microbiology</i> , 2000, 41, 290-294.	1.0	56
81	The NucE and NucD lysis proteins are not essential for secretion of the <i>Serratia marcescens</i> extracellular nuclease. <i>Microbiology (United Kingdom)</i> , 1999, 145, 1209-1216.	0.7	3
82	<i>Serratia marcescens</i> and its extracellular nuclease. <i>FEMS Microbiology Letters</i> , 1998, 165, 1-13.	0.7	85
83	Orotidine-5-phosphate decarboxylase from <i>Pseudomonas aeruginosa</i> PAO1: Cloning, overexpression, and enzyme characterization. <i>Current Microbiology</i> , 1994, 29, 353-359.	1.0	8
84	<i>Serratia marcescens</i> and its extracellular nuclease. , 0, .		2
85	Correlates and Disparities of COVID-19 Vaccine Hesitancy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	74